基线严重度对社会焦虑障碍CBT与候补对照症状变化关联的调节作用
该系统综述与个体患者数据荟萃分析纳入12项随机对照试验共1246例成人社交焦虑障碍患者,比较认知行为治疗与候补名单对照。结果显示CBT与LSAS症状改善显著相关,且基线LSAS分数调节该关联,基线症状越重者绝对症状改善越大,提示可放心向重度患者提供CBT。
要点
- CBT与候补对照相比LSAS改善显著(b=-20.3,Cohen d=-0.95)。
- 基线LSAS调节疗效(b=-0.22,P=.009),重度者绝对改善更大。
- 临床可放心向重度社交焦虑障碍患者提供CBT。
核心结论
- 在社交焦虑障碍成人中,基线症状严重度越高,CBT后绝对症状改善越大,但相对效应不随严重度增加。
研究设计与样本
- 系统综述与个体患者数据荟萃分析,检索PubMed、PsycInfo、Embase和Cochrane Library(1990年1月1日至2023年1月13日),纳入12项随机对照试验共1246例成人社交焦虑障碍患者。
- 纳入标准为比较CBT与候补名单对照、使用LSAS、成人原发临床诊断社交焦虑障碍的随机临床试验。
- 采用两阶段个体患者数据荟萃分析,随机效应模型评估CBT与LSAS基线至治疗后变化的关联及基线LSAS与条件的交互效应。
主要发现
- CBT与候补对照相比,LSAS基线至治疗后变化显著(b=-20.3;95%CI,-24.9至-15.6;P<.001;Cohen d=-0.95;95%CI,-1.16至-0.73)。
- 基线LSAS分数调节CBT与候补名单在症状减轻上的差异(b=-0.22;95%CI,-0.39至-0.06;P=.009)。
- 重度社交焦虑障碍患者CBT后候补对照症状减轻的Cohen d=-1.13(95%CI,-1.39至-0.88),轻度患者为Cohen d=-0.54(95%CI,-0.80至-0.29)。
关键数值与推荐
- 纳入研究使用Liebowitz社交焦虑量表(LSAS)测量症状严重度。
- 主要结局为LSAS基线至治疗后症状严重度变化。
- 共纳入12项研究、1246例患者,平均(SD)年龄35.3(10.9)岁,女性738例(59.2%)。
临床怎么用
- 临床可自信地向重度社交焦虑障碍症状患者提供CBT,因其绝对症状改善更大。
- 基线严重度可作为预后参考,但不应据此限制轻度患者接受CBT。
局限性
- 仅纳入比较CBT与候补名单对照、使用LSAS的随机对照试验,可能限制结论外推。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Social anxiety disorder (SAD) can be adequately treated with cognitive behavioral therapy (CBT). However, there is a large gap in knowledge on factors associated with prognosis, and it is unclear whether symptom severity predicts response to CBT for SAD. OBJECTIVE: To examine baseline SAD symptom severity as a moderator of the association between CBT and symptom change in patients with SAD. DATA SOURCES: For this systematic review and individual patient data meta-analysis (IPDMA), PubMed, PsycInfo, Embase, and the Cochrane Library were searched from January 1, 1990, to January 13, 2023. Primary search topics were social anxiety disorder, cognitive behavior therapy, and randomized controlled trial. STUDY SELECTION: Inclusion criteria were randomized clinical trials comparing CBT with being on a waiting list and using the Liebowitz Social Anxiety Scale (LSAS) in adults with a primary clinical diagnosis of SAD. DATA EXTRACTION AND SYNTHESIS: Authors of included studies were approached to provide individual-level data. Data were extracted by pairs of authors following the Preferred Reporting Items for Systematic Reviews and Meta-analyses reporting guideline, and risk of bias was assessed using the Cochrane tool. An IPDMA was conducted using a 2-stage approach for the association of CBT with change in LSAS scores from baseline to posttreatment and for the interaction effect of baseline LSAS score by condition using random-effects models. MAIN OUTCOMES AND MEASURES: The main outcome was the baseline to posttreatment change in symptom severity measured by the LSAS. RESULTS: A total of 12 studies including 1246 patients with SAD (mean [SD] age, 35.3 [10.9] years; 738 [59.2%] female) were included in the meta-analysis. A waiting list-controlled association between CBT and pretreatment to posttreatment LSAS change was found (b = -20.3; 95% CI, -24.9 to -15.6; P < .001; Cohen d = -0.95; 95% CI, -1.16 to -0.73). Baseline LSAS scores moderated the differences between CBT and waiting list with respect to pretreatment to posttreatment symptom reductions (b = -0.22; 95% CI, -0.39 to -0.06; P = .009), indicating that individuals with severe symptoms had larger waiting list-controlled symptom reductions after CBT (Cohen d = -1.13 [95% CI, -1.39 to -0.88] for patients with very severe SAD; Cohen d = -0.54 [95% CI, -0.80 to -0.29] for patients with mild SAD). CONCLUSIONS AND RELEVANCE: In this systematic review and IPDMA, higher baseline SAD symptom severity was associated with greater (absolute but not relative) symptom reductions after CBT in patients with SAD. The findings contribute to personalized care by suggesting that clinicians can confidently offer CBT to individuals with severe SAD symptoms.
引用
- Scholten W, Seldenrijk A, Hoogendoorn A, et al. Baseline Severity as a Moderator of the Waiting List-Controlled Association of Cognitive Behavioral Therapy With Symptom Change in Social Anxiety Disorder: A Systematic Review and Individual Patient Data Meta-analysis. JAMA Psychiatry. 2023. PMID: 37256597. doi:10.1001/jamapsychiatry.2023.1291
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。